BiTE for acute myeloid leukemia (AML) targets proteins expressed on most AML blasts, such as CD33 and CD123, and cell surface proteins that are often overexpressed or mutated on AML blasts, such as FLT3 [72]. The gene discussed is CD33; the disease is acute myeloid leukemia.